Topiramate as an example of using generics in the treatment of epilepsy

Rudakova I.G.; Kotov A.S.; Belova Iu.A.

doi:https://doi.org/

Rudakova I.G.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo, Moskva

Kotov A.S.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Belova Iu.A.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Topiramate as an example of using generics in the treatment of epilepsy

Authors:

Rudakova I.G., Kotov A.S., Belova Iu.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(3): 38‑43

Read: 4712 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rudakova IG, Kotov AS, Belova IuA. Topiramate as an example of using generics in the treatment of epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(3):38‑43. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Autonomic cardiovascular disorders in patients with epileptic and psychogenic non-epileptic seizures: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):13-20

Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77

Stress and sleep: Neurobiological aspects and modern options of insomnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Early diagnosis and effective therapy of diabetic polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68

A personalized approach to the diagnosis of epilepsy in obese children. Laboratory Service. 2025;(1):5-12

Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry. Russian Cardiology Bulletin. 2025;(1):22-38

Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coronary intervention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200

Influence of griseofulvin on intestinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):185-190

Postoperative peritonitis: epidemiology, diagnosis, surgical treatment and prognosis. Pirogov Russian Journal of Surgery. 2025;(6):104-111

Abstract:

Causes of losing the pharmacological remission with duration of more than one year have been analyzed in 220 patients with epilepsy. The most often cause of losing control of seizures was switching from brand antiepileptic drugs to generic analogue (60,4% of patients) with 28,2% of them being switched to topiramate generics. The results of switching of 160 patients from the brand form of topiramate (topamax) to its generics were compared to those in the control group of 52 patients who continued to receive the original form. As a result of switching the remission was lost in 75,6% of patients, epileptic status in 3,75%; 51,9% of patients needed emergency care and hospitalization. Switching back to original medication was done in 86,2% of patients with the following increasing of initial doses of topamax in 58,0% and transition from mono- to polytherapy in 60,0%. The baseline level of seizure control has been achieved only in 32,9% of patients.

Keywords:

epilepsy

treatment

generics

Authors:

Rudakova I.G.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo, Moskva

Kotov A.S.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Belova Iu.A.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Close metadata

References:

Meshkovskii A.P. Mesto dzhenerikov v lekarstvennom obespechenii. Farmateka 2003; 3: 103-104.
Kharchuk S.M., Gekht A.B., Belousova E.D. i dr. Ratsional'naya farmakoterapiya epilepsii: traditsionnye i novye podkhody k preodoleniyu starykh problem. Remedium 2007; 11: 1: 16-17.
Basak A.K., Raw A.S., Al Hakim A.H. et al. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications. Adv Drug Deliv Rev 2007; 59: 64-72.
Berg M.J., Gross R.A., Tomaszewski K.J. et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71: 525-30.
Besag F.M. Is generic prescribing acceptable in epilepsy? Drug Saf 2000; 23: 173-182.
Birkett D.J. Generics - equal or not? Austr Prescr 2003; 26: 85-87.
Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003; 25: 1578-1592.
Burkhardt R.T., Leppik I.E., Blesi K. et al. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004; 63: 1494-1496.
Chen M.L., Shah V., Patnaik R. et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 2001; 18: 1645-1650.
Crawford P., Feely M., Guberman A., Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006; 15: 165-176.
Donnelly R., Meredith P.A., Miller S.H. et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther 1993; 54: 303-310.
Duh M.S., Paradis P.E., Latremouille-Viau D. et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009; 72: 2122-2129.
European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Note for guidance on the investigation of bioavailability and bioequivalence, CPMP/EWP/QWP/1401/98, July 2001.
French J.A., Gidal B.E. Antiepileptic drug interactions. Epilepsia 2000; 41; supl 8: 30-36.
Furberg B.D., Furberg C.D. Are all drugs of a class interchangeable? In: Evaluating Clinical Research: All that Glitters is not Gold. New York: Springer 2007; 115-119.
Genazzani A.A., Pattarino F. Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint. Drugs R D. 2008; 9: 65-72.
Kramer G., Biraben A., Carreno M. et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy & Behavior 2007; 11: 46-52.
Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003; 25: 2575-2590.
Meyer G.F. History and regulatory issues of generic drugs. Transplantation Proceedings 1999; 31: Suppl. 3A: 10-12.
Meyer M.C., Straughn A.B., Mhatre R.M. et al. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 1998; 15: 1787-1791.
Nakai K., Fujita M., Ogata H. New bioequivalence studies: individual bioequivalence and population bioequivalence. Yakugaku Zasshi 2000; 120: 1201-1208.
Nakai K., Fujita M., Ogata H. International harmonization of bioequivalence studies and issues shared in common. Yakugaku Zasshi 2000; 120: 1193-1200.
Olling M., Mensinga T.T., Barends D.M. et al. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 1999; 20: 19-28.
Rosenbaum D.H., Rowan A.J., Tuchman L., French J.A. Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 1994; 35: 656-660.
Scott T., Devine E.W., Barron J., Behm A. Original article Acute epilepsy Exacerbations in patients switched between A-rated anti-epileptic drugs Current. Medical Research & Opinion 2010; 26: 2: 455-463.
Wiecek A., Mikhail A. European regulatory guidelines for biosimilars. Nephrol Dial Transplant 2006; 21: Suppl 5: 17-20.
Wilner A.N. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004; 5: 995-998.
World Health Organization. Available at: http://www.who.int/ trade/glossary/story034/en/index.html.